Skip to content
Free nationwide delivery · Cash on Delivery availableFree delivery · COD
DealsAboutContact Orders
wellmart
All products All categories All brands All ingredients
Sign in
HomeShopIngredientsOrforglipron

Filters

Filters

Category

  • All categories
  • No matches.

Brand

  • No matches.

Max price: any

Availability

Orforglipron

1 product

Sort
PureBio Labs Orforglipron 6mg 90 Capsules
-60%
PureBio Labs

PureBio Labs Orforglipron 6mg 90 Capsules

Rs 7,000Rs 17,500
View Product
Deep dive

About Orforglipron

Everything you need to know about this ingredient — sourced from our editorial team and the brands we work with.

About this ingredient

Orforglipron is an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and Company. It acts on GLP-1 receptors involved in appetite regulation, satiety, and blood glucose control. In the United States, it was approved in April 2026 under the brand name Foundayo for long-term weight reduction and weight maintenance in eligible adults with obesity or overweight accompanied by at least one weight-related medical condition. Its use is intended to be combined with a reduced-calorie diet and increased physical activity. Orforglipron is a prescription medicine, not a dietary supplement, and it may cause significant adverse effects. Approval and availability can differ between countries, so its regulatory status in Pakistan should be confirmed with the Drug Regulatory Authority of Pakistan (DRAP) or a qualified healthcare professional before considering its use.

Health benefits

  • ✓⚖️ Approved in the United States for weight management in eligible adults
  • ✓🍽️ Acts on appetite and satiety pathways
  • ✓🩸 Influences blood glucose regulation through GLP-1 receptor activation
  • ✓💊 Available as an oral prescription medicine in authorized markets
  • ✓🩺 Can support long-term weight management when used as prescribed
  • ✓⚠️ Benefits and suitability depend on individual assessment and medical supervision

Common uses

  1. 1💊 Prescription treatment for eligible adults requiring weight management in authorized markets
  2. 2⚖️ Used alongside a reduced-calorie diet and increased physical activity
  3. 3🍽️ Acts on appetite and satiety pathways
  4. 4🩸 Studied for effects on glucose regulation
  5. 5🧪 Investigated in clinical research on obesity and type 2 diabetes
  6. 6📋 Requires prescription and monitoring by a qualified healthcare professional

How it works

Orforglipron activates GLP-1 receptors, which are involved in regulating appetite, food intake, and blood glucose. Its effects can increase feelings of fullness, reduce hunger, and influence the rate at which the stomach empties. These actions can help eligible patients reduce calorie intake and lose weight when the medicine is combined with dietary changes and increased physical activity. Orforglipron may also improve blood glucose regulation through GLP-1-related pathways. Individual responses vary, and the medicine is not suitable for everyone. It should be used only under an authorized prescription and according to the current prescribing information.

Recommended for

  • ♥Orforglipron may be prescribed to eligible adults who meet the approved criteria for weight management in a jurisdiction where the medicine is authorized. In the United States, Foundayo is indicated for adults with obesity or adults with overweight who also have at least one weight-related medical condition, alongside a reduced-calorie diet and increased physical activity. It is not intended for casual weight loss or unsupervised use. A qualified prescriber must assess medical history, current medicines, treatment goals, and potential risks before prescribing it. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 must not use Foundayo under its US prescribing information. Other important considerations include a history of pancreatitis, gallbladder disease, severe gastrointestinal problems, diabetes-related eye disease, and pregnancy.

Scientific information

Orforglipron is a small-molecule, non-peptide agonist of the GLP-1 receptor. Unlike peptide-based GLP-1 medicines, it is designed for oral administration. GLP-1 receptor activation affects appetite-related signaling, food intake, gastric emptying, and glucose-dependent insulin secretion. Clinical studies have investigated orforglipron for obesity and type 2 diabetes, with results indicating weight reduction in studied populations; however, outcomes depend on the dose, duration, patient characteristics, and treatment setting. The US Food and Drug Administration approved Foundayo for weight management in April 2026. This approval does not automatically establish approval in Pakistan or authorize its sale through supplement retailers. Its clinical use must follow the approved product label and applicable local regulations.

Safety information

Orforglipron requires medical supervision and is not appropriate for self-medication. The US prescribing information includes a boxed warning concerning the potential risk of thyroid C-cell tumors associated with GLP-1 receptor agonist activity in animal studies; the relevance to humans remains uncertain. Foundayo is contraindicated under the US label in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Other serious risks include pancreatitis, severe gastrointestinal reactions, dehydration-related kidney injury, low blood glucose when combined with certain diabetes medicines, allergic reactions, and gallbladder disease. The medicine may delay gastric emptying and affect the absorption of other oral medicines. It may cause fetal harm and should be discontinued when pregnancy is recognized, according to the US label. Patients should inform healthcare professionals about all medicines they take and any planned surgery or procedure requiring anesthesia. Do not use unverified products marketed as orforglipron or purchase prescription medicines from unregulated sellers.

Possible side effects

  • !Common adverse reactions reported with orforglipron include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, abdominal bloating, fatigue, belching, acid reflux, flatulence, and hair loss. Symptoms may be more noticeable during treatment initiation or dose increases. More serious complications can include pancreatitis, gallbladder problems, dehydration-related kidney injury, severe gastrointestinal symptoms, hypoglycemia when used with certain diabetes medicines, and serious allergic reactions. Persistent or severe abdominal pain, repeated vomiting, inability to keep fluids down, or signs of a severe allergic reaction require prompt medical attention. Any suspected adverse reaction should be discussed with the prescribing healthcare professional.

More about this ingredient

Orforglipron is an oral GLP-1 receptor agonist developed for medical weight management. It works through pathways involved in appetite, satiety, and blood glucose regulation and is marketed in the United States under the brand name Foundayo. The medicine received US FDA approval in April 2026 for eligible adults seeking long-term weight reduction and weight maintenance. Orforglipron is a prescription medicine rather than a nutritional supplement, and its suitability depends on individual health status and prescribing criteria. Consumers searching for Orforglipron in Pakistan should verify current DRAP registration, lawful availability, prescription requirements, and the authenticity of any product with a qualified healthcare professional. It should not be purchased or used as an unverified weight-loss product. Wellmart.pk can provide educational ingredient and medicine information, but any listing or availability claim should be verified against current Pakistani regulatory requirements.
Got questions?

Frequently asked questions

What is Orforglipron?

Orforglipron is an oral, non-peptide GLP-1 receptor agonist prescription medicine developed for weight management.

What is Orforglipron used for?

In the United States, it is approved for long-term weight reduction and weight maintenance in eligible adults with obesity or overweight accompanied by a weight-related medical condition.

Is Orforglipron a dietary supplement?

No. Orforglipron is a prescription medicine and should not be marketed or used as an ordinary dietary supplement.

How does Orforglipron work?

It activates GLP-1 receptors involved in appetite regulation, satiety, gastric emptying, and blood glucose control.

Is Orforglipron approved by the FDA?

Yes. The US FDA approved Foundayo (orforglipron) for weight management in April 2026.

Is Orforglipron available in Pakistan?

Its current registration and availability in Pakistan should be confirmed with DRAP or a qualified healthcare professional. US approval does not automatically establish Pakistani approval.

Does Orforglipron help with weight loss?

Clinical research supports weight reduction in studied populations, and it is approved for eligible adults in the United States. Results vary and require appropriate medical supervision.

Is Orforglipron used for type 2 diabetes?

Orforglipron has been studied in type 2 diabetes. The approved indications depend on the country and current product label, so confirm the authorized use locally.

Is Orforglipron a GLP-1 medicine?

Yes. It activates the GLP-1 receptor, although it is a small molecule rather than a peptide-based GLP-1 medicine.

Is Orforglipron taken orally?

Yes. The US-approved Foundayo formulation is an oral tablet taken once daily according to its prescribing information.
wellmart

Collections

    Help Desk

      Newsletter

      Get early access to drops & deals.

      © 2026 Wellmart.